Pelvic organ-preserving radical cystectomy (POPRC) for women may improve postoperative sexual and urinary functions without compromising the oncological outcome compared with standard radical cystectomy (RC).
Objective
To determine the effect of POPRC on sexual, oncological and urinary outcomes compared with RC in women who undergo standard curative surgery and orthotopic neobladder substitution for bladder cancer.
Evidence acquisition
Medline, Embase, Cochrane controlled trials databases and clinicaltrial.gov were systematically searched for all relevant publications. Women with bladder cancer who underwent POPRC or standard RC and orthotopic neobladder substitution with curative intent were included. Prospective and retrospective comparative studies and single-arm case series were included. The primary outcomes were sexual function at 6-12 months after surgery and oncological outcomes including disease recurrence and overall survival (OS) at >2 years. Secondary outcomes included urinary continence at 6-12 months. Risk of bias (RoB) assessment was performed using standard Cochrane review methodology including additional domains based on confounder assessment.
Evidence synthesis
The searches yielded 11 941 discrete articles, of which 15 articles reporting on 15 studies recruiting a total of 874 patients were eligible for inclusion. Three papers had a matched-pair study design and the rest of the studies were mainly small, retrospective case series. Sexual outcomes were reported in seven studies with 167/194 patients (86%) having resumed sexual activity within 6 months postoperatively, with median (range) patients' sexual satisfaction score of 88.5 (80-100)%. Survival outcomes were reported in seven studies on 197 patients, with a mean follow-up of between 12 and 132 months. At 3 and 5 years, cancer-specific survival was 70-100% and OS was 65-100%. In all, 11 studies reported continence outcomes. Overall, the daytime and night-time continence rates were 58-100% and 42-100%, respectively. Overall, the selfcatheterisation rate was 9.5-78%. Due to poor reporting and large heterogeneity between studies, instead of subgroup-analysis, a narrative synthesis approach was used. The overall RoB was high across all studies.
Conclusion
For well-selected patients, POPRC with orthotopic neobladder may potentially be comparable to standard RC for oncological
Introduction
Bladder cancer is a common disease in women, with 100 000 newly diagnosed cases each year and >35 000 deaths per year worldwide [1] . Two main aetiological factors for developing bladder cancer in women are tobacco smoking and the occupational exposure to chemicals accounting for about half of all cases [2, 3] . About 25% of the cases are muscle-invasive bladder cancer (MIBC) with a high risk of cancer-specific mortality. Radical cystectomy (RC) is the 'gold standard' management for high-risk urothelial carcinoma of the bladder (UCB). Standard RC for women includes removal of the bladder, urethra and adjacent vagina, uterus, distal ureters, and regional lymph nodes [4] .
Sexual dysfunction is prevalent after standard RC, and especially for younger patients, this is an important concern. Interest in patients' health-related quality of life (HRQoL) has promoted the trend towards pelvic organ-preserving techniques [5] . Better imaging methods, increased knowledge of the function of the pelvic structures, and improved surgical techniques have enabled less radical operative techniques for treating women with bladder cancer who need cystectomy. These less radical techniques involve preserving the neurovascular bundle, vagina, uterus or variations of any of the stated techniques. These modifications are collectively called pelvic organ-preserving techniques. Sexual functionpreserving techniques could potentially result in better HRQoL outcomes for sexual and urinary function after RC. However, even if such benefits are obtained, it would be important for oncological outcomes not to be compromised.
The objective of the present systematic review was to compare pelvic organ-preserving RC (POPRC) with standard RC in women who undergo curative surgery for bladder cancer, in terms of sexual, oncological, and urinary function outcomes. The review was commissioned and undertaken by the European Association of Urology (EAU) Muscle-invasive Bladder Cancer (MIBC) Guideline Panel, as part of its guideline update for 2016.
Evidence Acquisition

Search Strategy and Selection Criteria
The protocol for the systematic review has been published elsewhere [6] . A systematic literature search was performed up to 31 May 2016. The search strategy is described in Appendix 1. In brief, Medline (from 1946), Embase (from 1974), Cochrane controlled trials databases and clinicaltrial.gov (from 2000) were searched for all relevant publications. Both medical subject heading (MeSH) and free text terms, as well as variations of root word were searched. Key terms related to 'bladder cancer' or 'transitional cell carcinoma' were combined using the set operator 'AND' key terms related to 'cystectomy'. Animal studies, case reports and editorials were excluded. Due to the expected paucity of available studies, all study types, including randomised controlled trials (RCTs), non-randomised comparative studies (NRCS) and non-comparative studies (e.g., single-arm case series) without size limitation were included. No language restrictions were imposed. Studies published as conference abstracts only were also included. The search was complemented by additional sources, including the reference lists of included studies and a panel of experts (EAU MIBC Guideline Panel).
Types of participants
Women with MIBC or high-risk non-MIBC [UCB or squamous cell carcinoma (SCC) up to T3b, N1/Nx, M0] undergoing RC with curative intent (with or without neoadjuvant chemotherapy and adjuvant treatment) in the primary setting were included. Populations excluded were women with metastatic disease (all M sub-stages according to TNM criteria), salvage cystectomy, previous pelvic radiotherapy, and non-RC (e.g. partial cystectomy). If any of these excluded characteristics were present in the population, studies would still be included if they constituted <10% of the study population.
Types of interventions
The experimental intervention was RC with any pelvic-organ preserving technique (i.e. POPRC), including the following: neurovascular bundle-preserving, vagina-preserving or genitalia-sparing variations of any of the stated techniques; or any other sexual function-preserving technique as described by the trialists. The control or comparator intervention was standard RC. To minimise clinical heterogeneity the reconstructive intervention was orthotopic neobladder substitution in both experimental and control groups. Studies that performed POPRC combined with urinary diversion instead of orthotopic neobladder substitution were excluded.
Types of outcomes measures
The primary outcomes were:
1 Sexual function (as defined by the trialists, based on preoperative and postoperative assessment), measured by the use of standardised questionnaires, measured at 6-12 months; 2 Oncological outcomes, including disease recurrence (local or metastatic), measured at >2 years and reported as a point estimate or as disease-free interval; and overall survival (OS) at >2 years.
The secondary outcomes were:
1 Urinary function (as defined by the trialists, including the following measures: need for self-catheterisation, pad usage, incontinence questionnaires, night vs day continence, etc.), measured immediately postoperatively and at 6-12 months; 2 Additional oncological outcomes, including pathological outcomes, such as stage and grade, and positive margins of the surgical specimen.
Data Collection and Data Extraction
The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) process [7] was followed for reporting included and excluded studies (Fig. 1 ). Abstracts and full texts were reviewed independently by at least two reviewers (E.V., Y.N., or M.R.) for relevance to the defined inclusion and exclusion criteria. Disagreement was resolved by discussion or reference to an independent third party (T.L. or T.B.L.L.). The references cited in all full-text articles were also assessed to identify additional relevant articles. A data extraction form was developed a priori to collect information on study design, participant characteristics, characteristics of interventions, and outcome measures. Two reviewers independently extracted data relating to the pre-specified outcomes.
Assessment of Risk of Bias (RoB)
The RoB of each included study was assessed independently by at least two reviewers. RoB in NRCS was performed using a modified version of the Cochrane RoB tool for RCTs that included additional items to assess confounding bias. This was a pragmatic approach informed by the methodological literature pertaining to assessing RoB in NRCS [8, 9] . A list of the five most important confounders for harm and benefit outcomes were identified a priori by the EAU MIBC Guideline Panel and included age, clinical and pathological stage, performance status, type of intervention, and body mass index (BMI). RoB in single-arm case series was assessed using the following domains: selection bias (i.e. whether study participants were selected consecutively or were they representative of a wider patient population), attrition bias, selective outcome reporting, and whether an a priori protocol was available (i.e. indicating prospective study design) [10, 11] .
Data Analysis
A narrative synthesis of the evidence was performed. Metaanalysis was considered inappropriate because of the expected heterogeneity of populations, interventions, outcomes, and study designs. Descriptive statistics were used to summarise baseline characteristic data. For time-to-event data (e.g. survival analysis), estimates such as median survival or the percentage event-free (e.g. recurrence-free survival rate) at the pre-specified times points were extracted, if available. Adjusted and unadjusted hazard ratios (HRs) to estimate the size of intervention differences were extracted, if available. For categorical data, point estimates reported as proportions (%), risk ratios or odds ratios with 95% CIs were extracted, if available. For continuous outcomes, the mean difference with corresponding 95% CIs, and mean AE SD, or median AE interquartile range were extracted, if available. To explore the potential impact of clinical heterogeneity on outcomes, subgroup and/or sensitivity analyses were planned on the following variables: menopausal status, age, BMI, types of interventions, neoadjuvant chemotherapy, co-morbidities or performance status (or factors which can influence sexual function), pathological stage, grade, or carcinoma in situ (CIS), adjuvant treatment, and postoperative continence status.
Evidence Synthesis
Quantity of Evidence Identified
The study selection process is summarised in the PRISMA flow diagram (Fig. 1 ). In all, 11 937 articles were identified and screened; of these, 16 articles were eligible for full-text screening and 15 met the inclusion criteria [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] .
Characteristics of the Included Studies
Data were available for 874 patients from the 15 studies. We reviewed 12 retrospective case series [13, 14, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . The largest study recruited 86 patients [13] , whilst the smallest study recruited three patients only [17] . Six case series assessed vaginal-sparing RC [13, 14, [21] [22] [23] [24] . The age of the patients ranged from 60.8 to 68 years and the pathological stage was ≥T3 in 19-42% of the study population. Nervesparing RC was assessed by Nesrallah et al. [20] . The age of patients ranged from 42 to 77 years and the pathological stages were not reported. A third group of studies reported the results of genital-sparing RC [17] [18] [19] 25, 26] . There was a large variation in the age of the patients (20-80 years) and pathological bladder ≥T3 stage (7.7-100%).
RoB and Confounding Assessment
Figure 2 [12, 15, 16] presents the RoB assessment for the NRCS, and Fig. 3 [13, 14, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] for single-arm case series. The overall RoB for the NRCS was high or unclear, with all studies judged to have high confounding bias across most confounders. Conversely, the overall RoB for case series was low, with most domains being judged to be at low RoB except for an a priori protocol. Postoperative voiding outcomes were mainly appropriately measured and reported. In most studies, sexual function outcome was assessed by interviewing patients, which is more prone to bias. 
Comparisons of Interventions Results
Pathological outcomes
In all, 143 patients (34%) of all patients that underwent POPRC had ≥ pT3 and 52 (14%) had lymph node positivity ( Table 2) . CIS was found in 23 (7%) bladder specimens. The rate of positive surgical margins was reported in seven studies ranging from zero to 13.7%. In all, 13 studies reported the template of lymph node dissection (LND); 11 of these series 
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The final histology was mostly well reported ( Table 2 ). The oncological outcomes were reported for 850 patients and 80% (679 patients) had UCB. For 124 (15%) patients the histology was not specified but the pT-stage was given, 37 patients (4%) had a malignancy other than UCB, and 10 patients were operated with benign bladder disease.
Information about chemotherapy was poorly reported. Granberg et al. [22] and Moursy et al. [26] reported that three and two patients, respectively, received adjuvant chemotherapy. Neoadjuvant chemotherapy was described in studies by Horenblas et al. [17] and Koie et al. [18] . There were a small number of patients receiving chemotherapy without any adjustments.
Oncological Outcomes
In all, 11 studies [12, 14, 15, [17] [18] [19] [20] 22, 23, 25, 26] reported oncological outcomes of POPRC in women. Only the study reported by Large et al. [12] had a comparative design; the rest were small, single-arm case series.
Cancer-specific Survival (CSS) and OS
Survival outcomes for the 197 patients that underwent a POPRC, were available (Table 2) . Oncological outcomes were available at a mean follow-up of between 12 and 132 months. Only seven of 11 studies reported a mean follow-up of >36 months. Only one NRCS reported survival outcomes [15] . Ali-El-Dein et al. [15] reported 5-year CSS and OS outcomes only for genital-sparing RC without showing the outcomes of standard RC. In the discussion of this study, they mentioned that oncological results between the two groups were comparable.
Six surgical series [18, 20, 22, 23, 25, 26] reported mean survival outcomes. Both 5-year CSS and OS were similar to NRCS 70-88% and 65-83%, respectively. Worse oncological outcomes were associated with unfavourable pathological stage or lymph node involvement in several studies.
Local and Metastatic Recurrence
In NRCS, Large et al. [12] found no difference in the local recurrence rate between vaginal-sparing and standard RC groups (11.7% vs 10.5%, P = 0.88). Metastatic recurrence rates were not reported. Large et al. [12] Random sequence generation (selection bias) In case series, local recurrence ranged from zero to 13% [14, 18, 22, 26] and metastatic recurrence 9.5-24% [14, 18, 20, 22] . Time to local recurrence ranged from a median of 6-8 months in three studies [14, 18, 22] . Large et al. [12] reported on 42 patients with ≥pT3 with 11.7% local recurrences and found that compared with ≥pT3 patients that underwent standard RC, there was no difference in local recurrence-free survival (P = 0.61). Follow-up for continence evaluation ranged widely from 1 to 227 months. Continence outcome assessment and measurement were heterogeneous. Some used objective measures such as number of daily pads, whereas others used patient reported outcomes. Only Rouanne et al. [23] used a validated anonymous questionnaire to evaluate continence (Contilife). Nevertheless, definition of complete continence was common for nine studies, regardless of assessment methods, consisting of complete dryness.
Urinary Function Outcome
Only one study was a NRCS that recruited 13 patients and compared internal genital organ-sparing RC with anterior pelvectomy [15] , whilst 10 studies were case series. Ali-elDein et al. [15] retrospectively compared the urodynamic test results of 110 women having pelvic exenteration to 13 women that underwent POPRC. Urodynamic variables were similar in both groups. The NRCS reported day-and night-time continence rates in women receiving POPRC of 100% and 92%, respectively [15] . The continence outcomes of standard RC were not reported.
Day-time continence was reported in 10 case series [14, [17] [18] [19] [20] [21] [23] [24] [25] [26] and night-time continence in seven case series [17] [18] [19] [20] [21] 23, 26] . In the vaginal-sparing group, day-and nighttime continence ranged from 59% to 71% and 42-71%, respectively [14, 21, 23, 24] . In the nerve-sparing technique, Nesrallah et al. [20] reported 97% day-time continence and 86% night-time continence. Data from five genital-sparing case series showed day-and night-time continence rates of 64-100% and 50-89%, respectively [17] [18] [19] 25, 26] . Eight case series studies reported self-catheterisation rates ranging from zero to 30.7% [14, [19] [20] [21] [23] [24] [25] [26] .
In all, 10 studies were single-centre retrospective cohorts. Only three studies, with 94 cases, prospectively collected data. There was heterogeneity in patient selection, methods of data collection, and outcome assessment. For instance, patient selection was related to oncological status, excluding tumours located in the bladder neck or patients with diffuse CIS. Conversely, preoperative continence status, that may affect functional outcome, was not used as a selection criterion. Moreover, preoperative continence was not accurately assessed in most studies. Only Anderson et al. [21] collected data on preoperative continence. Gross et al. [24] assessed the urethral pressure profile preoperatively, and then analysed it as an outcome criterion, as an indirect measure of continence. Postoperatively continent patients had a longer preoperative functional urethral length compared with Granberg et al. [22] Gross et al. [24] Horenblas et al. [17] Koie et al. [18] Kulkarni et al. [19] Moursy et al. [26] Nesrallah et al. [20] Neymeyer et al. [13] Rouanne et al. [23] Wishahi et al. [25] A priori protocol? 3 (14) 1 (5) 1 (5) 6 2 (21) 7 (13) 1 (2) 7 (13) 8 (2-36) 8 (15) 2 (8) 5 years, Table 4 [13, [15] [16] [17] 23, 25, 26] presents the sexual function outcomes of POPRC in women. Data from seven studies reporting on 168 patients were included, two of them were NRCS [15, 16] and five were case series [13, 17, 23, 25, 26] .
Sexual Outcome
At the time of surgery, the mean patient age ranged from 37.9 to 64.8 years across studies. The mean duration of postoperative follow-up varied from 13.2 to 132 months. There was a minimum postoperative period of 6 months for sexual activity assessment across studies. However, baseline sexual function evaluation was lacking in most studies. Only Bhatt Dhar et al. [16] collected data at baseline and during follow-up.
At the date of analysis, a range of 58-100% of patients had resumed sexual activity. Satisfaction related to patients' sexuality was mentioned in five of the seven studies and the reported rates ranged from 80% to 100%. Only one study reported the postoperative delay (6 weeks) to regain sexual activity. Definition of sexual activity included either sexual intercourse and/or vaginal manipulation.
Most studies (four) used validated standardised questionnaires to assess sexual function (i.e. the FSFI and the Contilife). In these studies, the mean FSFI score ranged from 18/36 to 23.7/ 36. In the other three studies, sexual function was evaluated by a physician interview. Sexual outcome that was evaluated, was based on postoperative vaginal lubrication/normal orgasm [17] , patient's satisfaction of 'feeling of femininity' [13] or unchanged sexual life with related dyspareunia [26] .
Only two of the considered studies had a comparative design. Bhatt Dhar et al. [16] reported that female sexual function was preserved in all patients who received neurovascular preservation and declined in patients who underwent nonneurovascular preservation. Similarly, Ali-El-Dein et al. [15] assessed the FSFI parameters in women with genitalia-sparing cystectomy (n = 13) and other women with orthotopic neobladder without genital sparing (n = 110). They found that the mean FSFI scores in the study group were significantly higher than in RC women without genital sparing. The authors also report significant differences in favour of genital sparing cases in all domains of the FSFI.
Discussion
RC followed by orthotopic neobladder substitution is now an established type of urinary diversion in women. Despite the fact that first encouraging series of the POPRC were reported 20 years ago, we still consider this approach as experimental. The main concerns related to the POPRC are a potentially In the literature, according to single-centre series, the urethral recurrence rate in women with neobladders ranges between 0.6% and 4.3% [27] [28] [29] . The evidence reviewed here suggests that 0-13% of those having preserving techniques will have a local recurrence. As shown by Stein et al. [30] , patients with an uninvolved bladder neck rarely have urethral involvement of cancer. More recently, in a multicentre study by Gakis et al. [29] , it was reported that only the final positive surgical margin was associated with urethral recurrence. In a univariable analysis, involvement of the bladder trigone and positive nodes were not risk factors for urethral recurrence.
Clinical staging has a remarkable role in avoiding local invasion of the bladder cancer into the reproductive organs. Due to the anatomy, the most commonly reported local invasion occurs from the bladder base to the vagina [31, 32] .
In preoperative assessment, it should be taken into account that risk factors for gynaecological organ invasion include a palpable mass, hydronephrosis, and positive lymph nodes [31] . Evidence from previous studies suggests that the risk of secondary malignancy of genital organs after RC in women is low [33] .
According to a multi-institutional database of 888 consecutive patients undergoing standard RC for bladder cancer, the 5-year recurrence-free survival rate was 58% and the CSS was 66% [34] . Recurrence-free survival and OS in a large singlecentre study of 1054 patients was 68% and 66% at 5 years, and 60% and 43% at 10 years, respectively [35] . In all, 10 studies in the present review reported, besides functional outcomes, oncological outcomes. Independent of the preserving-technique, the oncological results were comparable to the traditional RC and the orthotopic neobladder.
The present systematic review reports daytime continence, night-time continence, and self-catheterisation rates of 57.1-100%, 42.9-100%, and 0-30.7%, respectively. By way of comparison, in a recent review of functional results of orthotopic neobladder in women, Hautmann et al. [36] reported daytime continence, night-time continence, and selfcatheterisation rates of 77-97%, 66-86%, 10-61%, respectively. Hence, these functional results are somewhat disappointing in the setting of a surgical procedure designed to improve them. However, one plausible explanation is that inclusion in the included studies was based on oncological criteria without regard to preoperative continence status. It is possible that the results are influenced by an impaired continence of the included population at baseline. It is recommended that that future studies report baseline and change from baseline data for continence outcomes. Moreover, continence was defined heterogeneously across the studies, and the follow-up duration was inadequate. Performing evaluation at 6-12 months, as reported in the included studies, may also lead to underestimation of the definitive continence rate. In summary, heterogeneity in the included populations continence outcome definition and measurement time-point means that it remains uncertain as to whether there is an improvement in continence outcomes linked to the POPRC.
Despite major pelvic surgery, Rouanne et al. [23] reported that most sexually active women were interested in preserving a good quality of sexual life. This response rate confirmed that overall HRQoL and sexual function in particular continue to be major issues for patients with cancer and cancer survivors. Although poorly identified, impaired sexual function has been recognised as the primary source of selfassessed distress among patients undergoing RC [37] [38] [39] .
Indeed, several anatomical factors have been identified to decrease postoperative sexual dysfunction: nerve-sparing cystectomy with conservation of the neurovascular bundles on the lateral walls of the vagina, preservation of the anterior vaginal wall, and vascularisation of the clitoris.
Ali-El-Dein et al. [15] hypothesised that preservation of the whole vagina and its freedom of any suture line was possibly the reason for early regaining of sexual activity, compared with those without genitalia preservation. Similarly, the authors reported significant differences in favour of genitalsparing cases in all domains evaluated by the FSFI.
However, we recommend that prospective multicentre studies, reporting baseline and postoperative data with validated questionnaires, are needed to assess the relationship between postoperative sexual outcomes and POPRC in women.
Limitations of the Study
This is the first systematic review of the evidence base for POPRC in women. Our comprehensive search strategy involving both female and male patients to avoid missing combined studies yielded only 15 studies. Most studies were retrospective and non-comparative with small numbers of investigated patients, meaning that any estimates are uncertain and likely to be biased. Furthermore, the optimal baseline and change from baseline measurements for the sexual and urinary function outcomes were mostly absent. Some of the studies did not report the final histology because they focused only on the functional outcomes. Included studies that did report the histology had included mostly patients with UCB and a few patients with SCC. Planned subgroup-analysis was not possible due to lack of information.
From the results of the present systematic review, none of the POPRC techniques (neurovascular bundle-preserving, vaginapreserving or genitalia-sparing) can be recommended over the others due to the lack of studies comparing different operation techniques. The nature of the comparison is bound to be biased, although it is the best that we can do using the available data, which has been systematically reviewed.
Heterogeneity in outcome definition, measurement and reporting hampers the usefulness of the current evidence base. A core outcome set, using the methodology outlined by the Core Outcome Measures in Effectiveness Trials (COMET) initiative [40] is needed to ensure that future studies address the outcomes that are important for decision-making for patients, clinicians, policy makers and healthcare funders, and are defined and measured consistently.
Conclusion
In women with high-risk bladder cancer, oncological and functional data from POPRC followed by reconstruction of the neobladder remains immature and requires prospective research to make comparisons with standard RC. However, for well-selected patients, sparing female reproductive organs during RC appears to be oncologically safe and provides improved functional outcomes. The overall quality of the evidence was low as the included studies were underpowered with a significant RoB and confounding. For the same reason it is difficult to define a preserving technique that performs better than others.
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